| People newly diagnosed with HIV, Kwa-Zulu Natal, South Africa | Household contacts, Pakistan | |||||
---|---|---|---|---|---|---|---|
CD4 < 100 | CD4 100–200 | CD4 200–350 | CD4 > 350 | Age < 5 years | Age 5–14 years | Age ≥ 15 years | |
Total evaluated | 379 | 442 | 785 | 1392 | 2194 | 4261 | 6648 |
Symptomatic TB at baseline, N (%) | 93 (24.5%) | 56 (12.7%) | 42 (5.4%) | 43 (3.1%) | 42 (1.9%) | 86 (2%) | 28 (0.4%) |
Subclinical TB diagnosed at baseline, N (%) | Â | Â | Â | Â | 19 (0.9%) | 58 (1.4%) | 29 (0.4%) |
Subclinical TB progressed to active within 3 months | 16 (4.2%) | 17 (3.8%) | 28 (3.6%) | 44 (3.2%) |  |  |  |
Followed to 6 months | 359 | 406 | 740 | 1312 | NA | NA | NA |
TB diagnoses, 3 to 6 months, N (% | 2 (0.6%) | 4 (1%) | 2 (0.3%) | 0 (0%) |  |  |  |
Followed to 12 months | 314 | 348 | 625 | 1096 | NA | NA | NA |
TB diagnoses, 6 to 12 months, N (% | 7 (2.2%) | 7 (2%) | 5 (0.8%) | 7 (0.6%) |  |  |  |
Estimated lifetime incidence (95%CI) of progression of latent infections present at enrollmenta | 4.7% (2.7–6.8%) | 4.9% (2.9–7.1%) | 3.0% (1.7–4.2%) | 2.5% (2.5–3.4%) | 0.6% (0.3–1.0%) | 3.7% (2.3–5.3%) | 1.2% (0.8–1.8%) |
Estimated subclinical prevalent cases per future latent progression | Â | Â | Â | Â | 1.4 | 0.4 | 0.4 |
Estimated subclinical progressors per latent progressor (95%CI)b | 0.9 (0.6–1.4) | 0.8 (1.5–1.2) | 1.2 (0.8–1.9) | 1.2 (0.9–1.9) | 0.7 (0.4–1.2) | 0.2 (0.1–0.3) | 0.2 (0.1–0.3) |